Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 879-886

  Kobayashi, Naoki ^a   Kobayashi, Hitomi ^a   Gu, Leo ^b   Malefyt, Thomas ^b   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Admunex Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; CD11A 237-246 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 139-151; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE SUBPOPULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYNAPSE; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANAPHYLAXIS; ANIMALS; ANTIGENS; ANTIGENS, CD11A; BODY WEIGHT; CAPSID PROTEINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; MICE; MICE, INBRED STRAINS; MODELS, IMMUNOLOGICAL; MOLECULAR SEQUENCE DATA; MYELIN PROTEOLIPID PROTEIN; OVALBUMIN; PEPTIDE FRAGMENTS; PEPTIDES; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; VACCINATION;

EID: 34547105068     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123257     Document Type: Article

References (42)

1. Bercovici N, Delon J, Cambouris C, Escriou N, Debre P, and Liblau RS (1999) Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice. Eur J Immunol 29:345-354.
2. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175.
3. Falk K, Rotzschke O, Santambrogio L, Dorf ME, Brosnan C, and Strominger JL (2000) Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides. J Exp Med 191:717-730.
4. Gerety SJ, Karpus WJ, Cubbon AR, Goswami RG, Rundell MK, Peterson JD, and Miller SD (1994) Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. V. Mapping of a dominant immunopathologic VP2 T cell epitope in susceptible SJL/J mice. J Immunol 152:908-918.
5. Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, and Claassen E (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 93:2499-2504.
6. Grakoui A, Bromley S, Sumen C, Davis MM, Shaw AS, Allen PM, and Dustin ML (1999) The immunological synapse: a molecular machine controlling T-cell activation. Science 285:221-227.
7. Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AV, t Hart B, and Amor S (2005) Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice. J Neuroimmunol 167:23-33.
8. Huang M, Matthews K, Siahaan TJ, and Kevil CG (2005) alpha L-integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium. Am J Physiol 288:G67-G73.
9. Inamura N, Mekori YA, Bhattacharyya SP, Bianchine PJ, and Metcalfe DD (1998) Induction and enhancement of Fc(epsilon)RI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1- and leukocyte function-associated antigen (LFA)-1-mediated heterotypic aggregation. J Immunol 160:4026-4033.
10. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, and Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276.
11. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, and Steinman L (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6:1176-1182.
12. Karin N, Mitchell DJ, Brocke S, Ling N, and Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J Exp Med 180:2227-2237.
13. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, and Hancock WW (1995) CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 155:4521-4524.
14. Kuchroo VK, Greer JM, Kaul D, Ishioka G, Franco A, Sette A, Sobel RA, and Lees MB (1994) A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 153:3326-3336.
15. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, and Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381.
16. Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, and Shaw AS (2002) T cell receptor signaling precedes immunological synapse formation. Science 295:1539-1542.
17. Legge KL, Min B, Bell JJ, Caprio JC, Li L, Gregg RK, and Zaghouani H (2000) Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J Exp Med 191:2039-2052.
18. Liblau RS, Tisch R, Shokat K, Yang X, Dumont N, Goodnow CC, and McDevitt HO (1996) Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci U S A 93:3031-3036.
19. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD, and Eisenbarth GS (2002) Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 110:1021-1027.
20. Luca ME, Kel JM, van Rijs W, Wouter Drijfhout J, Koning F, and Nagelkerken L (2005) Mannosylated PLP(139-151) induces peptide-specific tolerance to experimental autoimmune encephalomyelitis. J Neuroimmunol 160:178-187.
21. Margot CD, Ford ML, and Evavold BD (2005) Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J Immunol 174:3352-3358.
22. Monks CR, Freiberg BA, Kupfer H, Sciaky N, and Kupfer A (1998) Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82-86.
23. Neuhaus O, Farina C, Wekerle H, and Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-708.
24. Pedotti R, Mitchell D, Wedemeyer J, Karpuj M, Chabas D, Hattab EM, Tsai M, Galli SJ, and Steinman L (2001) An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2:216-222.
25. Pedotti R, Sanna M, Tsai M, DeVoss J, Steinman L, McDevitt H, and Galli SJ (2003) Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self-peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 4:2.
26. Perrin PJ, June CH, Maldonado JH, Ratts RB, and Racke MK (1999) Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 163:1704-1710.
27. Reddy J, Illes Z, Zhang X, Encinas J, Pyrdol J, Nicholson L, Sobel RA, Wucherpfennig KW, and Kuchroo VK (2004) Myelin proteolipid protein-specific CD4+CD25+ regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 101:15434-15439.
28. Rose JW, Welsh CT, Hill KE, Houtchens MK, Fujinami RS, and Townsend JJ (1999) Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis. J Neuroimmunol 97:110-118.
29. Samson MF and Smilek DE (1995) Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol 155:2737-2746.
30. Smith CE, Eagar TN, Strominger JL, and Miller SD (2005) Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 102:9595-9600.
31. Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PT, and Whitacre CC (2002) Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 169:2180-2188.
32. Stern JN, Illes Z, Reddy J, Keskin DB, Fridkis-Hareli M, Kuchroo VK, and Strominger JL (2005) Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 102:1620-1625.
33. Tuohy VK, Lu Z, Sobel RA, Laursen RA, and Lees MB (1989) Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 142:1523-1527.
34. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, and Miller SD (2000) Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 164:670-678.
35. Wang C, Gold BG, Kaler LJ, Yu X, Afentoulis ME, Burrows GG, Vandenbark AA, Bourdette DN, and Offner H (2006) Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 98:1817-1827.
36. Welsh CT, Rose JW, Hill KE, and Townsend JJ (1993) Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J Neuroimmunol 43:161-167.
37. Wildbaum G, Netzer N, and Karin N (2002) Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest 110:701-710.
38. Yu P, Gregg RK, Bell JJ, Ellis JS, Divekar R, Lee HH, Jain R, Waldner H, Hardaway JC, Collins M, et al. (2005) Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen. J Immunol 174:6772-6780.
39. Yusuf-Makagiansar H, Makagiansar IT, Hu Y, and Siahaan TJ (2001a) Synergistic inhibitory activity of α- and β-LFA-1 peptides on LFA-1/ICAM-1 interaction. Peptides 22:1955-1962.
40. Yusuf-Makagiansar H, Makagiansar IT, and Siahaan TJ (2001b) Inhibition of the adherence of T-lymphocyte to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1. Inflammation 25:203-214.
41. Yusuf-Makagiansar H and Siahaan TJ (2001) Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells. Pharmacol Res 18:329-335.
42. Zhang X, Reddy J, Ochi H, Frenkel D, Kuchroo VK, and Weiner HL (2006) Recovery from experimental allergic encephalomyelitis is TGF-beta dependent and associated with increases in CD4+LAP+ and CD4+CD25+ T cells. Int Immunol 18:495-503.